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ABSTRACT
Background: For proton therapy of paranasal tumors, field directions avoiding volumes that might
change during therapy are typically used. If the plan is optimized on the daily anatomy using daily
adapted proton therapy (DAPT) however, field directions crossing the nasal cavities might be feasible.
In this study, we investigated the effectiveness of DAPT for enabling narrow-field treatment
approaches.
Material and methods: For five paranasal tumor patients, representing a wide patient spectrum, ana-
tomically robust 4-field-star and narrow-field plans were calculated and their robustness to anatomical
and setup uncertainties was compared with and without DAPT. Based on the nominal planning CTs,
per patient up to 125 simulated CTs (simCTs) with different nasal cavity fillings were created and ran-
dom translations and rotations due to patient setup uncertainties were further simulated. Plans were
recalculated or re-optimized on all error scenarios, representing non-adapted and DAPT fractions,
respectively. From these, 100 possible treatments (60 GyRBE, 30 fx) were simulated and changes in
integral dose, target and organs at risk (OARs) doses evaluated.
Results: In comparison to the 4-field-star approach, the use of narrow-fields reduced integral dose
between 29% and 56%. If OARs did not overlap with the target, OAR doses were also reduced. Finally,
the significantly reduced target coverage in non-adapted treatments (mean V95 reductions of up to
34%) could be almost fully restored with DAPT in all cases (differences <1%).
Conclusions: DAPT was found to be not only an effective way to increase plan robustness to anatom-
ical and positional uncertainties, but also opened the possibility to use improved and more conformal
field arrangements.
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Introduction
Protons deliver highly conformal dose distributions to the
target while sparing organs at risk (OARs). This allows dose
escalation to the tumor and/or sparing of OARs for cases
that are clinically challenging [1–4]. This comes at the cost of
a high sensitivity to uncertainties along the beam path [5–9],
such that changes in the patient anatomy or positioning can
substantially affect the dose distribution [10]. One way to
mitigate this effect is to adapt the treatment as soon as ana-
tomical changes occur.
The importance of considering plan adaptation is widely
recognized and several proton centers have defined adaptive
workflow protocols [10–12]. If anatomical changes are
expected, patients are regularly monitored with 3D imaging
during treatment and, if necessary, the treatment is re-opti-
mized offline. Typically, it takes a few days from image acqui-
sition until a new plan is delivered, which is suboptimal for
anatomical changes that vary on a daily basis (e.g. nasal
cavity fillings). For such cases, the ideal approach would be a
daily adapted proton therapy (DAPT), delivering a plan opti-
mized every day based on a 3D, in-room image acquired dir-
ectly before each fraction. With DAPT, both the daily
anatomy and patient setup variations can be directly
included in the daily plan optimization, allowing for reduced
margins and irradiation of surrounding healthy tissue. As
such, previous studies showed that a highly efficient DAPT
workflow including the plan-of-the-day generation and valid-
ation might be feasible in less than five minutes after in-
room 3D imaging [13,14].
In addition, DAPT could also enable the use of alterna-
tive field arrangements (e.g. narrow-angle approaches)
which optimally minimize dose to healthy tissue, but is
sensitive to anatomical changes without DAPT. In this
study, we have investigated the potential advantage of a
DAPT enabled narrow-angle approach for treating para-
nasal tumors, taking into account both anatomical and
setup uncertainties.
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Five paranasal patients, all previously treated with proto-
ntherapy, were included in this work to cover the spectrum
of tumor sizes, locations and initial nasal cavity fillings seen
in our clinical practice (Figure 1). Patients 1 and 2 had both
initially empty nasal cavities and very different tumor sizes;
patients 3 and 4 had large tumor volumes in different loca-
tions, but half-filled cavities at their planning CTs; patient 5
had a moderately sized tumor and initially completely filled
nasal cavities.
Plans
Intensity modulated proton therapy plans were optimized on
the planning CT with an in-house developed planning sys-
tem using the ray casting algorithm [15,16]. The Bragg peaks
were positioned with a lateral spacing of 4mm and water
equivalent range separations of 2.5mm (proximal spots) to
5.0mm (deep spots). All plans were calculated to deliver a
total dose of 60 GyRBE (RBE ¼ 1.1) in 2 GyRBE/fraction.
Two field geometries were investigated: a 4-field-star
approach and a narrow-field approach using three fields. The
4-field-star approach, consisting of two anteriorly and poster-
iorly inclined fields from the left and right, was optimized on
a planning target volume (PTV) based on a homogeneous
expansion of 5mm around the clinical target volume (CTV),
which is our current clinical practice. The narrow-field plans
were calculated using field-specific PTVs generated by
expanding the CTV isotropically by 1mm and adding a range
specific distal margin of 3%. With this, the patient setup was
corrected for by the DAPT approach, allowing for the reduced
PTV margin, while the 3% expansion in field direction deals
with residual systematic range errors. The field angles were
chosen to minimize the distance to the tumor from the
patient surface, and therefore came predominantly from the
anterior direction. Robust optimization was not used for any
planning approach. Supplement 1 shows results of a pre-study
analyzing the reduction of integral dose resulting from margin
reduction or field geometry for patient 1.
Implementation of anatomical and setup changes
To simulate different cavity fillings, the planning CTs were
modified to generate simulated CTs (simCTs) using an in-
house developed program. Previously contoured left, right
and central nasal cavities were first overwritten with an
HU of –970 (air), with the internal voxels being then layer-
wise overwritten with an HU of 30 to model mucus accu-
mulation [17]. Depending on the volume of the nasal cav-
ity, up to 125 simCTs were generated (125, 100, 48, 60
and 36 for patients 1–5, respectively). Potential daily setup
errors were simulated by shifting each field’s isocenter ran-
domly along each cartesian axis using a standard deviation
(r) of 1.57mm. This value was based on the residual intra-
fractional movement of previously treated patients at our
institute [18,19]. Similarly, rotational uncertainties were esti-
mated based on our setup protocol, where rotations
greater than 1.15 were typically corrected. As such, we
assumed that 98% (2r) of setups were within this angular
error, leading to an r of 0.57 for rotational setup errors.
Rotational errors were randomly sampled from this
Gaussian distribution and added to the planned gantry
and couch rotations. Fraction doses were then generated
by combining each simCT with five random translational
and/or rotational error scenarios per simCT, leading to a
pool of up to 625 anatomical and positioning scenarios
per patient. Supplement 2 shows results of a pre-study
evaluating the separate effects of setup or anatomical
changes on treatment doses for patient 1.
Simulation of non-adapted and adapted treatments
The dosimetric effects of anatomical and setup uncertain-
ties on each fraction of non-adapted treatments were esti-
mated by recalculating the initial plans on different
simulated daily scenarios, while DAPT fraction doses were
simulated by re-optimizing each plan on the daily scenario,
using the same margins, optimization constraints and field
arrangements as the initial plan. From this database of
fraction doses, treatment doses were generated by adding
up 30 randomly selected fraction doses of the non-
adapted and DAPT scenarios, respectively. This was
repeated 100 times for each patient and plan geometry,
simulating 100 non-adapted and DAPT treatments. This
database of non-adapted and DAPT fraction doses (625,
500, 240, 300 and 180 for patients 1–5, respectively),
allowed for the evaluation of a wide variety of possible
treatments per patient and plan.
Figure 1. Representative slices of the five patients selected for this study. Patients 1 and 2 both had initially empty nasal cavities but large and small tumors,
respectively. Patients 3 and 4 both had half filled cavities and large tumor. In addition, the tumor of patient 4 is partly located outside (posterior) the nasal cavities.
For patient 5, the nasal cavities were initially filled.
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Dose evaluation
For plan evaluation, healthy tissue integral dose and dose
conformity indices (CIs) at the 95% and 50% isodoses
(VIsodose/VTarget, excluding dose in air) and CTV coverage as
measured by V95 (the volume receiving 95% of the prescrip-
tion dose) and D98 (the dose that 98% of the CTV receives)
were considered. Sparing of relevant OARs (chiasma and
brainstem) were evaluated and compared to each original
treatment plan as reference. Statistical significance (5%) of
differences between DAPT and non-adapted CTV parameters
over all simulated treatments of each patient has been inves-
tigated with a paired, two sided Wilcoxon’s signed rank test
in Matlab (MathWorks, Natick, MA, USA).
Results
Differences in integral dose between the 4-field-star plan
optimized with the clinical PTV, and the narrow-field
approach with reduced field specific PTV, are shown in
Table 1. For all patients, the narrow-field approach reduced
integral dose of the initial plan by 29–56%. Additionally, the
CI at the 50% isodose level (CI50%) was reduced by 17–46%,
and CI10% by 33–60%.
Figure 2 shows the combined effect of anatomical and
setup changes with and without DAPT for each patient.
Without adaption, differences in CTV coverage were patient
dependent. While for patient 2, a reduction in V95 of 34% in
comparison to the nominal plan was observed, patient 5
showed only negligible differences. Despite these large varia-
tions, DAPT could restore the planned CTV coverage in all
cases (V95 differences <1%). Indeed, statistically significant
differences between the non-adapted and DAPT treatments
within patients in favor of adaption were observed in all
CTV parameters.
OAR doses depended for both approaches mainly on the
target and field geometry. The use of narrow-field
approaches had a large potential to spare OARs. For
instance, brainstem D2 was reduced in three out of five
cases by up to 25% (patient 3), especially if the brainstem
was close to the target. Similarly, in three out of five cases,
the dose to the chiasma was reduced. For the remaining two
cases, where the chiasm was attached to or surrounded by
the target volume, a similar OAR sparing was achieved by
both field approaches. Although DAPT did not recover OAR
doses to those of the nominal plan, in most cases it provided
improved organ sparing in all treatment simulations.
Discussion
We have compared treatment doses considering daily ana-
tomical and setup variations with and without DAPT for two
planning approaches. Our simulations demonstrated that
DAPT mitigated daily positioning errors, allowing for substan-
tial reduction of PTV margins, thus decreasing integral dose
while preserving target coverage throughout the treatment
(Figure 2). Moreover, we showed that DAPT enabled the use
of nominally un-robust field arrangements, which could
reduce the integral dose even further. For example, for
patient 1, dose to healthy tissue decreased by 26% by using
DAPT enabled margin reduction alone, and by 49% if com-
bined with a narrow-field approach (Supplement 1). Over all
patients, integral dose was reduced by 29–56% using the
narrow-field approach combined with DAPT (Table 1).
We also demonstrated the dangers of this approach with-
out DAPT. In the case of a plan optimized on empty, but
applied to filled cavities, D98 to the CTV would reduce by up
to 32% for the 4-field approach and by more than 51% for
the narrow-field approach (Figure 3, patient 1). This was in
line with previous work showing that the 4-field-star was
relatively robust to anatomical changes [5].
Interestingly, variations in CTV coverage over the 100
sampled treatments were in some cases larger than 10%
within individual patients, indicating the substantial and
unpredictable effect of cavity changes on proton plans. The
magnitude of these variations depended on the amount of
cavity filling in the original planning CT. If the planning CT
had empty cavities (patients 1 and 2), changes lead to distal
under-dosage of the CTV and larger variations. Patients with
initially half-filled cavities (patient 3), or with the CTV only par-
tially overlapping with the cavities (patient 4), showed a less
pronounced decrease. Patients with initially filled cavities
(patient 5) were more robust in terms of CTV coverage but
were more sensitive to potential overshoot into healthy tissue
when the cavities emptied. With DAPT however, excellent tar-
get coverage was preserved for all planning approaches, even
with substantially reduced PTV margins (see Figure 2).
Clearly, our non-adapted simulations were a worst-case
approximation. Typically, for paranasal tumors, regular on-
treatment-CTs are clinically acquired such that plans could
be adapted within a few days [10]. Nevertheless, DAPT is the
best solution to mitigate such changes, especially those that
occur on a daily basis. In addition, daily optimization of the
plan could help exploit anatomies that are more favorable
for treatment. For instance, if the cavities were empty in the
initial CT, sharp bone/air interfaces locally distorted the
Bragg peak, potentially affecting both the conformation and
Table 1. Integral dose and conformity index at 50% and 10% isodose level of the 4-field-star initial treatment plans with homogeneous margin and the nar-
row-field plans with reduced margin.
Patient
Integral dose/Gyl CI10 CI50
Narrow-field 4-Field-star Narrow-field 4-Field-star Narrow-field 4-Field-star
1 24.0 45.7 3.6 6.4 2.3 3.3
2 6.3 13.5 10.5 26.2 4.5 6.7
3 12.3 27.8 5.0 12.5 2.9 4.5
4 19.8 28.0 10.4 15.5 5.2 6.3
5 33.2 51.8 5.2 7.8 3.1 3.8
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homogeneity of dose to the target volume. If the cavities
filled during treatment however, density heterogeneity
reduced, resulting in a more conformal and homogenous
dose to the tumor and improved sparing of OAR (see
Figure 2).
Variable cavity fillings in this study were modeled using
artificially modified CTs [17], assuming an equally distributed
probability for each filling scenario, resulting in drastic day-
to-day changes. Although observed for some patients at our
clinic, such changes could be considered as a worst-case
scenario. In addition, irregular cavity filling, patient weight
changes or tumor growth/shrinkage were not considered.
However, there is no reason to believe that these could not
also be compensated using a DAPT approach as demon-
strated here for variable cavity filling. Finally, it was demon-
strated that even if the patient anatomy did not change
during treatment, with a DAPT approach the patient would
still benefit from reduced integral dose.
As all beams came from the anterior direction, they also
all stopped in the posterior area of the target volume, and
regions of enhanced linear energy transfer (LET) from all
beams were therefore concentrated in this same region. This
was in contrast to the 4-field-star approach, where the
beams came equally from both sides of the patient and dis-
tributed and diluted regions of enhanced LET around the
periphery of the target volume. As such, the narrow-field
approach might be more sensitive to distal end biological
effects. This could be dealt possibly by reducing healthy tis-
sue tolerances to distally positioned OARs, or by including
LET into the optimization to re-distribute it away from critical
organs [20].
We acknowledge that alternative methods to mitigate
anatomical and positional changes have been suggested.
Some authors proposed to include anatomical changes dir-
ectly in the optimization algorithm by including multiple CT
scenarios [17,21] or to adjust daily patient positioning to
reduce the differences between planned and daily dose in
the presence of anatomical changes [22]. However, Van De
Water et al. [17] compared, for the same field arrangement,
the robustness of anatomically robust optimized and daily
Figure 2. Differences in CTV D98, V95 and selected OAR parameters of 100 simulated treatments for the narrow-field plan with reduced margin and the 4-field-
star with clinical PTV margin. Parameters from original plans are marked with circles. Outliers are marked with red crosses. CTV D98 and V95 for the non-adapted
and daily adapted treatments doses differ significantly (significance level 5%).
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adapted proton plans. They demonstrated that, even though
using an anatomical robust optimization was a valid strategy
to mitigate the effect of anatomy, DAPT, even without the
added benefits of a more conformal beam approach, had
the advantage of reducing integral dose and improving dose
conformability compared to robust optimization.
The clinical implementation of DAPT presents some chal-
lenges, for instance daily 3D imaging with high enough qual-
ity for replanning as well as contour propagation, fast plan
optimization, measurement free quality assurance (QA) and
accurate dose accumulation across multiple 3D data sets.
For daily imaging, there are three possibilities: In-room
CT, cone beam CT (CBCT) or on-board MR imaging. The use
of in-room CT currently guarantees the most accurate defin-
ition of proton stopping power, and with a low-dose proto-
col, it is possible to limit the imaging dose to the patient to
below 1 mGy per CT [23,24], similar to that delivered with
CBCT [25]. CBCT for adaption is currently under investigation
but extracting density information with the same accuracy as
with CT [26–30] remains challenging. The use of MRI for daily
imaging clearly has advantages of no imaging dose, but is
currently only under investigation [31,32].
As for fast planning and plan QA, we have previously
demonstrated that the complete optimization of plans can
be performed in just a few seconds [13], whereas efficient
independent dose calculations, based on machine control
files, provided a fast and sensitive alternative to plan specific
QA measurements [14,33]. Finally, although accurate contour
propagation and dose accumulation for deformable geome-
tries are still challenging [34], for the paranasal sinuses
spatial transformations between daily datasets are predomin-
antly rigid, simplifying both processes considerably. As such,
we believe that a highly efficient, DAPT workflow for the
treatment site investigated in this work is a realistic prospect
in the near future.
In conclusion, daily plan adaptation has been demon-
strated to be a useful technique to mitigate anatomical
changes, and could be the key for enabling the safe use of
improved field arrangements for proton therapy that would
normally be considered un-robust.
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